Herein, we report the synthesis of mixed-ligand Cu(II) complexes of metformin and ciprofloxacin drugs together with 1,10-phenanthroline as a co-ligand. The synthesized complexes were characterized using different spectroscopic and spectrometric techniques. cytotoxic activity against human breast adenocarcinoma cancer cell line (MCF-7) as well as antibacterial activity against two gram-negative and two gram-positive bacterial strains were also investigated. The analyses of the experimental results were supported using quantum chemical calculations and molecular docking studies against estrogen receptor alpha (ERα; PDB: 5GS4). The cytotoxicity of the [Cu(II) (metformin) (1,10-phenanthroline)] complex (), with IC of 4.29 µM, and the [Cu(II) (ciprofloxacin) (1,10-phenanthroline)] complex (), with IC of 7.58 µM, were found to be more effective than the referenced drug, cisplatin which has IC of 18.62 µM against MCF-7 cell line. The molecular docking analysis is also in good agreement with the experimental results, with binding affinities of -7.35, -8.76 and -6.32 kcal/mol, respectively, for complexes , and cisplatin against ERα. Moreover, complex showed significant antibacterial activity against (inhibition diameter zone, IDZ, = 17.3 mm), (IDZ = 17.08 mm), and (IDZ = 17.33 mm), at 25 μg/ml compared to ciprofloxacin (IDZ = 20.0, 20.3, and 21.3 mm), respectively. Our BOILED-egg model indicated that the synthesized metal complexes have potentially minimal neurotoxicity than that of cisplatin.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557196PMC
http://dx.doi.org/10.3389/fchem.2022.1028957DOI Listing

Publication Analysis

Top Keywords

antibacterial activity
8
molecular docking
8
110-phenanthroline] complex
8
complexes
5
cytotoxic mixed-ligand
4
mixed-ligand complexes
4
complexes cuii
4
cuii combined
4
combined experimental
4
experimental computational
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!